Critically, a recent study of the TNF-α antagonist infliximab in otherwise healthy patients with major depression demonstrated that the antidepressant activity of this drug was dependent on the level of inflammatory markers at baseline (Raison et al., 2013). This evidence concerns the gene TNF and major depressive disorder.